ArticleBlood advances2023
Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries.
Article in Blood advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study.Blood advances · 2026Trial
- Incremental eligibility criteria for the BMT CTN 1507 haploidentical trial for children with sickle cell disease.Blood advances · 2024Trial
- The SickleFit Tele-Exercise Program for older adults with sickle cell disease: feasibility, acceptability, safety study.Blood red cells & iron · 2026Article
- Half a century of pneumococcal vaccination in sickle cell disease: Are we winning the battle or losing immunity?Vaccine · 2026Review
- Three-year safety, efficacy, and renal outcomes of mitapivat treatment in sickle cell disease: results from the phase 2 open-label study.Haematologica · 2026Article
- Estimated glomerular filtration rate discordance and cardiopulmonary morbidity in sickle cell disease.Blood advances · 2026Article
- Cerebral arteries in mice with sickle cell disease are exposed to larger areas of low wall shear stress.American journal of physiology. Heart and circulatory physiology · 2026Article
- Article
- Patient Experiences of Acute Pain Communication in Sickle Cell Disease and Perspectives on Improving Clinician Communication.Journal of clinical psychology in medical settings · 2026Article
- Hematopoietic Cell Transplantation for Sickle Cell Disease.Children (Basel, Switzerland) · 2026Review
- Acute Chest Syndrome in Children with Sickle Cell Disease: A Narrative Review.Children (Basel, Switzerland) · 2026Review
- Understanding the impact of social determinants of health in hematology: a scoping review of trends across journals and over time.Blood advances · 2026Article
- Article
- Transformative therapies for sickle cell disease.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- Outcomes of hematopoietic stem cell transplantation in adult sickle cell disease patients: A Single-Center experience from India.Annals of hematology · 2026Article
- Mechanism-informed transition from pediatric to adult care in sickle cell disease: a case study.BMC health services research · 2026Article
- Economic Burden of Sickle Cell Disease: A Retrospective Study of Pediatric and Adult Individuals With Medicaid Coverage From 2016 to 2020.American journal of hematology · 2026Article
- Experiences of family building counseling and perceptions of reproductive technology among adults with sickle cell disease.PloS one · 2026Article
- Decoding thalassemia and sickle cell disease: advances in molecular technologies for comprehensive variant detection.Frontiers in genetics · 2026Review
- Murine Models of Transfusion-Induced Red Blood Cell Alloimmunization.Methods in molecular biology (Clifton, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To our knowledge, we report the first population-based period life table, the expected lifetime survival for Medicare and Medicaid beneficiaries with sickle cell disease (SCD), and the disparities in survival by insurance types in the United States. We constructed a retrospective cohort of individuals with diagnosed SCD receiving common care (any real-world patterns of care except transplant) based on nationwide Medicare and Medicaid claim data (2008-2016), covering beneficiaries in all 50 states. We analyzed lifetime survival probabilities using Kaplan-Meier curves and projected life expectancies at various ages for all, stratified by sex and insurance types. Our analysis included 94 616 individuals with SCD that have not undergone any transplant. Life expectancy at birth was 52.6 years (95% confidence interval: 51.9-53.4). Compared with the adults covered by Medicaid only, those covered by Medicare for disabilities or end-stage renal disease and those dually insured by Medicare and Medicaid had significantly worse life expectancy. Similarly, for beneficiaries aged ≥65 years, these 2 insurance types were associated with significantly shorter life expectancy than those enrolled in Medicare old age and survivor's insurance. Our study underscores the persistent life expectancy shortfall for patients with SCD, the burden of premature mortality during adulthood, and survival disparities by insurance status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.